Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Silo Pharma, Inc. (SILO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1720-0.0116 (-6.32%)
At close: 03:30PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1836
Open0.1810
BidN/A x N/A
AskN/A x N/A
Day's Range0.1650 - 0.1810
52 Week Range0.1320 - 0.4950
Volume153,436
Avg. Volume113,485
Market Cap16.972M
Beta (5Y Monthly)-1.90
PE Ratio (TTM)5.55
EPS (TTM)0.0310
Earnings DateNov 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for SILO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SILO PHARMA INC
    Analyst Report: Constellation Brands IncConstellation is a global manufacturer and marketer of wine, spirits, and beer with a wide range of brands, including Clos du Bois, Ruffino, Robert Mondavi, Kim Crawford and SVEDKA vodka. The company also owns the rights to brew and market Modelo Mexican beers (including Corona) in the United States.
    Rating
    Fair Value
    Economic Moat
    8 months agoArgus Research
View more
  • GlobeNewswire

    Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

    Englewood Cliffs NJ, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received its first ketamine shipment and initiated loading ketamine into their Z-Pod® transdermal technology. Eric Weisblum, CEO of Silo Pharma stated “The commencement of Novel Ketamine loaded Z-Pods is a pivotal advancement for administering Ket

  • GlobeNewswire

    Silo Pharma Reports Third Quarter Results and Operating Highlights

    Englewood Cliffs, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today reported its financial results for the third quarter 2021 and gave an update on recent progress in its business. Operating Highlights Entered sponsored research agreement with Columbia University to develop psychedelic therapeutics for Alzheimer’s Disease and received an option to license assets currently

  • GlobeNewswire

    Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease

    Agreement Provides for Option to License Alzheimer’s TherapeuticEnglewood Cliffs, NJ, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has entered into a sponsored research agreement with Columbia University pursuant to which Silo has been granted an option to license certain assets currently under development, including Alzheimer’s disease. This agreement

Advertisement
Advertisement